← Back to patent-cliff list

Foscenvivint

Tier C — Watch / trade

Foscenvivint

Prism Pharma Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:CREBBP, CTNNB1

Indications (approved):Hepatitis C, Liver cirrhosis, Hepatitis B, Biliary cirrhosis, Colorectal cancer, Solid tumour, Acute myeloid leukaemia, Chronic myeloid leukaemia

Regional status

US
Discontinued
2012-07-01
EU
-
China
-
Japan
Phase II
2018-07-24

Synthetic routes & intermediates1 routes

Originator routes × 0Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 7 · Total yield /
OP-724-001645-36-3OP-724-00266-77-3OP-724-003952110-63-3OP-724-00471989-38-3OP-724-0051002131-07-8OP-724-0061002131-08-9OP-724-00735737-10-1OP-724-0081002131-09-0OP-724-0091002131-10-3OP-724-0101002131-11-4API · Foscenvivint
CodeCAS No.Intermediate
OP-724-001645-36-32,2-diethoxyethan-1-amine
OP-724-00266-77-31-naphthaldehyde
OP-724-003952110-63-32,2-diethoxy-N-(naphthalen-1-ylmethyl)ethan-1-amine
OP-724-00471989-38-3(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)phenyl)propanoic acid
OP-724-0051002131-07-8(9H-fluoren-9-yl)methyl (S)-(3-(4-(tert-butoxy)phenyl)-1-((2,2-diethoxyethyl)(naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)carbamate
OP-724-0061002131-08-9(S)-2-amino-3-(4-(tert-butoxy)phenyl)-N-(2,2-diethoxyethyl)-N-(naphthalen-1-ylmethyl)propanamide
OP-724-00735737-10-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid
OP-724-0081002131-09-0(9H-fluoren-9-yl)methyl (S)-(3-((3-(4-(tert-butoxy)phenyl)-1-((2,2-diethoxyethyl)(naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)amino)-3-oxopropyl)carbamate
OP-724-0091002131-10-3(S)-2-(3-aminopropanamido)-3-(4-(tert-butoxy)phenyl)-N-(2,2-diethoxyethyl)-N-(naphthalen-1-ylmethyl)propanamide
OP-724-0101002131-11-4(S)-2-(3-(3-benzylureido)propanamido)-3-(4-(tert-butoxy)phenyl)-N-(2,2-diethoxyethyl)-N-(naphthalen-1-ylmethyl)propanamide

Frequently asked questions

What are the approved indications of Foscenvivint?

Approved indications include: Hepatitis C, Liver cirrhosis, Hepatitis B, Biliary cirrhosis, Colorectal cancer, Solid tumour, Acute myeloid leukaemia, Chronic myeloid leukaemia.

When does the Foscenvivint patent expire?

No public expiry year is available for Foscenvivint yet; this page updates once verified.

How many synthesis routes are recorded for Foscenvivint?

1 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Foscenvivint intermediates?

All intermediates in Foscenvivint routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Foscenvivint intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-18